-
Posted by
Two Blokes May 22, 2025 -
Filed in
Stock
-
4 views
Capricor's lead asset, deramiocel, targets DMD-related cardiomyopathy and faces key FDA milestones (ADCOM, PDUFA) in 2025. A strong cash position and partnership with Nippon Shinyaku provide financial stability but limit direct revenue potential from U.S. and Japan sales. Clinical data shows deramiocel slows disease progression by 52%, but regulatory approval and market adoption remain uncertain.
